In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit ...
1Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 2Center for Human Immunobiology, Department of Medicine, Feinberg ...
1Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational ...
Cancer Discov (2026) 16 (1): OF1.
1Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, New York. 2Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, ...
1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California. 2Cancer Institute, Stanford University School of Medicine, Stanford, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results